Jazz Pharmaceuticals JAZZ Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued liabilities?
- Jazz Pharmaceuticals (JAZZ) reported accrued liabilities of -$7.9M in Q1 2026.
- How has Jazz Pharmaceuticals's accrued liabilities changed year-over-year?
- Jazz Pharmaceuticals's accrued liabilities decreased by 104.4% year-over-year, from $181M to -$7.9M.
- What is the long-term trend for Jazz Pharmaceuticals's accrued liabilities?
- Over 2 years (2021 to 2025), Jazz Pharmaceuticals's accrued liabilities has grown at a -26.4% compound annual growth rate (CAGR), from $142.36M to $77.1M.
- What does accrued liabilities mean?
- The change in the amount the company owes for expenses that have been incurred but not yet paid.
- How do you interpret accrued liabilities?
- Increases often reflect growing operational scale or timing differences in payroll and tax accruals.
- How does accrued liabilities compare across companies?
- Common across all sectors; trends should align with the company's growth and operational complexity.